- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 215/60 - N-oxydes
Détention brevets de la classe C07D 215/60
Brevets de cette classe: 47
Historique des publications depuis 10 ans
|
7
|
7
|
1
|
3
|
1
|
2
|
3
|
2
|
3
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Zydus Lifesciences Limited | 121 |
7 |
| Astellas Pharma Inc. | 1057 |
2 |
| BIAL - Portela & CA, S.A. | 221 |
2 |
| Cadila Healthcare Limited | 313 |
2 |
| Exelixis, Inc. | 400 |
2 |
| Incyte Corporation | 1039 |
2 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2915 |
2 |
| Firmenich Incorporated | 155 |
2 |
| Laurel Therapeutics Ltd. | 6 |
2 |
| BASF SE | 21098 |
1 |
| Merck Sharp & Dohme Corp. | 2189 |
1 |
| Pfizer Inc. | 3401 |
1 |
| Bayer Cropscience AG | 1983 |
1 |
| Bayer Schering Pharma AG | 363 |
1 |
| Bayer Pharma AG | 1048 |
1 |
| Board of Regents, The University of Texas System | 5946 |
1 |
| Vertex Pharmaceuticals Incorporated | 1630 |
1 |
| Korea Advanced Institute of Science and Technology | 4467 |
1 |
| University of South Florida | 1849 |
1 |
| Department of Veterans Affairs | 113 |
1 |
| Autres propriétaires | 13 |